Pancreatic Cancer Research

ResearcherUniversity of RochesterActive in the last 2 years

Calvin Lloyd Cole

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7365-9506; OpenAlex author ID A5004242073, A5122827313; NIH RePORTER profile ID 14582465. Sources: OpenAlex.

Their work

Papers
3 (first author 0, last author 2)
Trials
0
Grants
1
Labs led
1
Collaborators
4
Papers, trials and grants by year

2021: 1 paper · 2022: none · 2023: none · 2024: 1 paper · 2025: 1 grant · 2026: 1 paper

Papers 3

  1. Ablation of tumor-derived IGFBP-3 attenuates cancer-associated skeletal muscle wasting in murine pancreatic cancer. Last author DOI 10.1152/ajpcell.00421.2025↗
  2. Validation of dual energy X-ray absorptiometry for longitudinal quantification of tumor burden in a murine model of pancreatic ductal adenocarcinoma. Last author DOI 10.1371/journal.pone.0292196↗
  3. Increased myocellular lipid and IGFBP-3 expression in a pre-clinical model of pancreatic cancer-related skeletal muscle wasting. Co-author DOI 10.1002/jcsm.12699↗

Grants 1

  1. Training and Research on Mechanisms of Pancreatic Cancer Associated Muscle Wasting and Related Therapies K01CA240533↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zachary R. Sechrist · 2 shared papers, 2024–2026 · strength 0.67
  2. David C. Linehan · 1 shared paper, 2021 · strength 0.12
  3. Joseph D. Murphy · 1 shared paper, 2021 · strength 0.12
  4. Scott A. Gerber · 1 shared paper, 2021 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.